



Vaccines and Global Health: The Week in Review
27 January 2024 :: Issue 735
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at <https://centerforvaccineethicsandpolicy.net>. This blog allows full text searching of over 27,000 entries.

Comments and suggestions should be directed to

David R. Curry, MS

Editor and

Executive Director

Center for Vaccine Ethics & Policy

david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.*

Support this knowledge-sharing service: *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

:: [Think Tanks](#)

Milestones, Perspectives

.....
.....

WHO – 154th session of the Executive Board

The 154th session of the Executive Board takes place on **22–27 January 2024**. Proceedings were webcast from [this page](#) which now includes recordings of all sessions.

Main Documents page: https://apps.who.int/gb/e/e_eb154.html

.....

WHO Executive Board appoints Regional Directors for Eastern Mediterranean, South-East Asia, and Western Pacific regions

23 January 2024 *News release*

Three new Regional Directors were appointed today by WHO's Executive Board to lead the Organization in the Eastern Mediterranean, South-East Asia, and Western Pacific Regions. Regional Directors are nominated by Regional Committees and appointed by the Executive Board.

Dr Hanan Hassan Balkhy will serve as Regional Director for the Eastern Mediterranean, Ms Saima Wazed will serve as Regional Director for South-East Asia, and Dr Saia Ma'u Piukala will serve as Regional Director for the Western Pacific, all starting on 1 February 2024. Each Regional Director serves for a five-year term.

"I congratulate our three new Regional Directors on their appointment. I wish them much luck in their new roles and look forward to working with them to advance our mission to achieve Health for All." WHO Director-General Dr Tedros Adhanom Ghebreyesus said.

From the Eastern Mediterranean Regional Office in Cairo, Egypt, Dr Hanan Balkhy will direct international health work in 22 countries and territories with 745 million people.

A graduate of King Abdulaziz University in Jeddah, Dr Balkhy completed her paediatric residency training at Massachusetts General Hospital in Boston, USA, and completed a paediatric infectious diseases fellowship with the Cleveland Clinic Foundation and Case Western Reserve University, also in the USA. She has served as Assistant Director-General for Antimicrobial Resistance at WHO headquarters since 2019. Over 20 years of her career, she has led many public health initiatives in her country, the Kingdom of Saudi Arabia. Previously, she was Executive Director for Infection Prevention and Control at the Saudi Arabian Ministry of National Guard. She led the Gulf Cooperation Council Centre for Infection Control and the WHO Collaborating Centre on Infection Prevention and Control and Antimicrobial Resistance.

From the South-East Asia Regional Office in New Delhi, India, Ms Saima Wazed will direct international health work in 11 countries with over 2 billion people.

She holds a bachelor degree and a master's degree in clinical psychology from Barry University in Florida, USA, and is a candidate for a doctorate in organizational leadership from Barry University. She has served as Advisor to the Director-General of WHO on Mental Health and Autism. Previously, she was Chief Advisor on the National Mental Health Strategic Plan for the Government of Bangladesh, and Chairperson of the National Advisory Committee on Autism and Neurodevelopmental Disorders. She was also Associate Fellow in the Global Health Programme at Chatham House, and Chairperson of the Shuchona Foundation in Bangladesh.

From the Western Pacific Regional Office in Manila, Philippines, Dr Saia Ma'u Piukala will direct international health work across 37 countries and areas with almost 1.9 billion people. A politician, public health leader and surgeon with nearly 30 years of experience, Dr Piukala served as Minister of Health of Tonga. He trained in medicine and surgery at the Fiji School of Medicine and was Medical Superintendent at Tonga's main referral hospital. He also served in the Legislative Assembly of Tonga, and championed initiatives on noncommunicable diseases, safe surgery, climate change and health, and disaster preparedness and response. He served as a designated member of Tonga on the WHO's Executive Board.



Featured Analysis

[100 Days Mission – Implementation Report – 2023](#)

Reducing the impact of future pandemics by making diagnostics, therapeutic, and vaccines available within 100 days

An independent report from the International Pandemic Preparedness Secretariat

PDF: <https://d7npznm5zvwd.cloudfront.net/prod/uploads/2024/01/3rd-100DM-Implementation-Report-IPPS-WEB.pdf>

Executive Summary

The 100 Days Mission (100DM) remains a crucial ambition in the wake of COVID-19's profound global impact. With 1.6 million lives lost¹ before the first vaccine's availability, and a staggering US\$12.5 trillion economic loss forecasted by 2024², the urgency for faster diagnostic, therapeutic, vaccine (DTV) development is undeniable³. As shown by the data in our 100DM scorecard, despite the lessons of COVID-19 we simply do not have approved, widely accessible, DTVs to respond to a pandemic from any other pathogen.

2023 PROGRESS AGAINST 100DM OBJECTIVES

In 2023, the International Pandemic Preparedness Secretariat (IPPS) tracked progress through research, interviews, and partner feedback; focusing on key determinants of progress such as funding, political support, and leadership.

Despite a challenging backdrop of competition for funding and so called 'pandemic fatigue' setting in, there have still been areas of progress toward a 100DM ready world in several areas:


:: Structural progress in the implementation of the 100DM, with the creation of the 100DM Science and Technology Expert Group (STEG), which has been driving progress through five subgroups, a published opinion piece in The Lancet and catalysing scientific exchange on some of the most challenging aspects of the mission, including via an event on the margins of the UN General Assembly 2023

:: The independent nature of the IPPS has also enabled the mission to be put on a shared global and regional footing. In the course of 2023, informative discussions were facilitated with regional partners through a series of listening exercises, aimed at better understanding regional capacities and challenges in implementing a 100DM preparedness framework. A key takeaway from these discussions is that any global solutions have to be translated into regionally appropriate strategies if we are to truly make an impact at a national or community level. Simultaneously, regional, national and community strategies work to inform global solutions.

:: Continued political support from Japan's G7 presidency and India's G20 presidency. in the alignment of this year's G7 and G20 agendas, facilitated discussions on surge financing, access to medical countermeasures MCMs and a potential future medical countermeasures network to replace the Access to COVID-19 Tools Accelerator (ACT-A), as well as commitments to the aims of the 100DM.

:: Vaccines research has seen promising progress with the US Food and Drug Administration (FDA) approval of a Chikungunya vaccine and Phase 1 trials beginning for Crimean-Congo Haemorrhagic fever, supplemented by multiple new Coalition for Epidemic Preparedness Innovations (CEPI) partnerships around the globe working towards optimising vaccine production covering everything from simplified administration routes to sustainable regional manufacturing strategies.

:: Nascent beginnings of a more coordinated approach to pandemic therapeutics, through the development of the 100DM Therapeutics Roadmap and the collaboration of multiple partners around this effort. Industry groups, international organisations and publicly funded research groups have come together to map a route to achieving the goal of having at least two 'Phase 2 ready' therapeutic candidates for each of the priority pathogen families.



Featured Analysis

[The State of Innovation in Vaccines and Prophylactic Antibodies for Infectious Diseases](#)

BIO INDUSTRY ANALYSIS December 2023

by David Thomas, CFA and Chad Wessel

Executive Summary

Pipeline & Investment

The global clinical pipeline for infectious disease vaccines consists of 249 active novel clinical-stage programs that are company sponsored. There are 31 infectious diseases represented in the clinical pipeline for which there is no currently available approved vaccine. The clinical pipeline has breadth, but lacks the depth likely required for successful product development for many important pathogens.

- For programs against viral pathogens, there are 187 clinical-stage programs. This consists of 69 SARS-CoV-2 vaccines, 84 for other RNA viruses (more than half of these for influenza, RSV, and HIV), and 34 DNA virus vaccines (half of these target HPV and Varicella-Zoster).

- For programs against bacterial pathogens, there are 44 clinical-stage programs. Although 18 total bacterial pathogens are targeted, more than half of the programs target *Streptococcus pneumoniae*, *Mycobacterium tuberculosis*, and meningococcus.
- For programs against parasitic pathogens, there are eight clinical-stage programs for malaria and schistosomiasis.
- There are 10 novel combination vaccines in development covering a total of 10 pathogens.

There is a wide range of vaccine modalities in the clinical pipeline, including 87 protein-based vaccines, (24 are part of virus-like particles (VLPs), 53 RNA-based vaccines (40 mRNA and 13 saRNA), 27 recombinant viral vector-based vaccines, 24 glyco-conjugate vaccines, 14 inactivated and 14 live attenuated viral vaccines, 12 DNA vaccines, 12 whole cell vaccines, and seven peptide vaccines.

Clinical success rates have been above average for vaccines during the period 2013-2022. With an 11% likelihood of FDA approval (LOA) from Phase I, vaccines outperformed non-vaccine biologics, which have a 7.6% LOA over the same time frame. By comparison, novel small molecules across all diseases had only 5.6% LOA.

Venture capital investments in global companies with infectious disease vaccine programs totaled \$6.5 billion over the last 10 years. This represents 3.4% of total venture capital raised for biopharmaceutical companies during the same period. By contrast, oncology drug development companies raised \$72.6 billion over the last decade, a 12-fold greater investment than in vaccines. Public companies with infectious disease vaccine programs raised \$8.7 billion, \$3.2 billion from IPOs and \$5.5 billion from secondary offerings. \$6 billion of the \$8.7 billion was raised during the COVID-19 pandemic.

The clinical pipeline for prophylactic antibodies is small relative to vaccines, with only 16 in clinical-stage development. However, the antibody pipeline targets 11 different pathogens.

Prophylactic antibodies have been used in broad populations to protect against seven unique pathogens.

In total, vaccines for 34 unique pathogens have been approved in the U.S. or globally. Licensed vaccines utilize a wide range of modalities: direct antigen delivery (protein, carbohydrate, pathogen inactivation and pathogen attenuation) and indirect antigen delivery (mRNA and viral vector-based vaccines).

Proposed Solutions to Expand the Depth/Breadth of the Vaccine Pipeline

:: Capitalize on use of Platform Technologies:

Platform technologies can speed development of novel approaches to improve efficacy and/or safety of vaccines, spur investment in new technologies in disease areas that have been difficult to tackle and help in pandemic preparedness. The policy environment must facilitate the use of platform technologies to spur investment in R&D across viral families.

:: Expand Access to Vaccines:

Given the broad benefits of primary prevention to individuals and society, especially for persons with underlying chronic conditions, facilitating access to immunizations through both financial policies and policies that increase the types of vaccinators (for example pharmacists) will have a significant impact on overall healthcare outcomes and costs.

:: Rebuild Vaccine Confidence Worldwide:

Combatting vaccine misinformation and disinformation and bolstering vaccine confidence is crucial to realizing the broadest benefits of vaccines and a stronger vaccine infrastructure overall.

:: Evolving ACIP and NITAG Review Processes:

Evaluation and recommendation by ACIP and other NITAGs define the size and patient utilization for the vaccine market. This process must adapt to the changing vaccine landscape and create a predictable review environment that encourages increased investment in the space.

COMPANY-SPONSORED GLOBAL CLINICAL PIPELINE FOR NOVEL VACCINES

Pathogen Type	Phase I	Phase II	Phase III	BLA	Total
Non-CoV-2 RNA viruses	49	22	10	3	84
SARS-CoV-2 RNA virus	32	23	14	0	69
DNA viruses	14	14	6	0	34
Bacteria	12	20	11	1	44
Parasites	4	4	0	0	8
Multiple Pathogen Types	8	2	0	0	10
Total	119	85	41	4	249

Figure 4. The company-sponsored global vaccine clinical pipeline by pathogen type (top) and phase (bottom) as of July 2023. Only novel vaccines for infectious disease are included.



Featured Journal Content

[Strategic vaccine stockpiles for regional epidemics of emerging viruses: a geospatial modeling framework](#)

Colin J. Carlson, Romain Garnier, Andrew Tiu, Stephen Luby, Shweta Bansal
medRxiv 2024.01.19.24301505; doi: <https://doi.org/10.1101/2024.01.19.24301505>

Abstract

Multinational epidemics of emerging infectious diseases are increasingly common, due to anthropogenic pressure on ecosystems and the growing connectivity of human populations. Early and efficient vaccination can contain outbreaks and prevent mass mortality, but optimal vaccine stockpiling strategies are dependent on pathogen characteristics, reservoir ecology, and epidemic dynamics. Here, we model major regional outbreaks of Nipah virus and Middle East respiratory syndrome, and use these to develop a generalized framework for estimating vaccine stockpile needs based on spillover geography, spatially-heterogeneous healthcare capacity and spatially-distributed human mobility networks. Because outbreak sizes were highly skewed, we found that most outbreaks were readily contained (median stockpile estimate for MERS-CoV: 2,089 doses; Nipah: 1,882 doses), but the maximum estimated stockpile need in a highly unlikely large outbreak scenario was 2-3 orders of magnitude higher (MERS-CoV: ~87,000 doses; Nipah ~1.1 million doses). Sensitivity analysis revealed that stockpile needs were more dependent on basic epidemiological parameters (i.e., death and recovery rate) and healthcare availability than any uncertainty related to vaccine efficacy or deployment strategy. Our results highlight the value of descriptive epidemiology for real-world modeling applications, and suggest that stockpile allocation should consider ecological, epidemiological, and social dimensions of risk.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This project was made possible with financial support provided by the Coalition for Epidemic Preparedness Innovations. CJC was additionally supported by NSF BII 2213854.

.....
.....
.....

Polio – PHEIC

Polio this week as of 24 Jan 2024 - GPEI

Summary of new polioviruses this week, cases and positive environmental isolates:

- Pakistan: nine WPV1-positive environmental samples
- Algeria: one cVDPV2-positive environmental sample
- Congo: one cVDPV2-positive environmental sample
- Côte d’Ivoire: four cVDPV2-positive environmental samples
- DR Congo: one cVDPV1 case
- Egypt: one cVDPV2-positive environmental sample
- Guinea: two cVDPV2-positive environmental samples
- Indonesia: one cVDPV2 case
- Mauritania: one cVDPV2-positive environmental sample
- Sudan: four cVDPV2-positive environmental samples
- Zimbabwe: one cVDPV2 case

.....
.....

Contents [click to move among sections]

:: [*Milestones, Perspectives*](#)

:: [*WHO*](#)

:: [*Organization Announcements*](#)

:: [*Journal Watch*](#)

:: [*Pre-Print Servers*](#)

.....
.....

WHO & Regional Offices [to 27 Jan 2024]

<https://www.who.int/news>

Selected News/Announcements/Statements

28 January 2024 Statement

[Joint Message by Dr Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization and Mr Yohei Sasakawa, WHO Goodwill Ambassador for Leprosy Elimination](#)

25 January 2024 Departmental news

[WHO releases a web version of the second edition of its Global Accelerated Action for the Health of Adolescents \(AA-HA!\) guidance](#)

24 January 2024 Statement

[WHO and partners bring fuel to Al-Shifa, as remaining hospitals in Gaza face growing threats](#)

23 January 2024 News release

[WHO Executive Board appoints Regional Directors for Eastern Mediterranean, South-East Asia, and Western Pacific regions](#)

.....

WHO Regional Offices

Selected Press Releases, Announcements

WHO African Region

:: 26 January 2024

[Tackling challenges to improve cholera treatment in Zambia's hardest-hit district](#)

:: 25 January 2024

[Angola reinforces cholera preparedness and response measures](#)

:: 24 January 2024

[Ramping up response to curb Zimbabwe cholera outbreak](#)

:: 22 January 2024

[Cameroon kicks off malaria vaccine rollout](#)

WHO Region of the Americas PAHO

:: [Antimicrobial resistance, and climate change key issues for the Americas at 154th WHO Executive Board](#)

Geneva, Switzerland, 27 January 2024 (PAHO) – Accelerating action to tackle the escalating threat posed by antimicrobial resistance (AMR) and ensuring that health equity is taken into consideration in national climate change adaptation and mitigation efforts were among the top issues discussed at the World Health Organization's 154th Executive...

:: [PAHO and International Hospital Federation sign agreement to strengthen hospital management in the Americas](#)

Washington DC, 25 January 2024 (PAHO)- The Pan American Health Organization (PAHO) and the International Hospital Federation (IHF) signed a technical cooperation agreement to strengthen hospital management capacity in the region, especially in Latin America and the Caribbean. The collaboration will focus on three core aims: supporting the...

WHO South-East Asia Region SEARO

:: 23 January 2024 News release

[Ms Saima Wazed appointed WHO Regional Director for South-East Asia](#)

WHO European Region EURO

Website not responding at inquiry.

WHO Eastern Mediterranean Region EMRO

:: [Dr Hanan Balkhy is appointed WHO Regional Director for the Eastern Mediterranean](#)

23 January 2024

:: [WHO and partners bring fuel to Al-Shifa, as remaining hospitals in Gaza face growing threats](#)

23 January 2024

WHO Western Pacific Region

:: [Dr Saia Ma'u Piukala appointed WHO Regional Director for the Western Pacific](#)

23 January 2024 News release

.....

WHO - Emergency situation reports

No new digest content identified.

.....

Disease Outbreak News (DONs)

Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

No new digest content identified.

.....

Weekly Epidemiological Record

<https://www.who.int/publications/journals/weekly-epidemiological-record>

Vol. 99, No. 04, pp. 23–48 26 January 2024

<https://iris.who.int/bitstream/handle/10665/375827/WER9904-eng-fre.pdf>

:: Editorial

:: Examining the threat of cyber-attacks on health care during the COVID-19 pandemic

:: Understanding disinformation in the context of public health emergencies: the case of COVID-19

.....

New WHO Publications

<https://www.who.int/publications/i>

Selected

25 January 2024

[Nineteenth meeting of the WHO Vector Control Advisory Group](#)

25 January 2024

[Towards a malaria-free world: elimination of malaria in Uzbekistan](#)

25 January 2024

[Mekong malaria elimination: epidemiology summary, volume 23, July–September 2023](#)

25 January 2024

[Evidence and research gaps identified during development of policy guidelines for tuberculosis, 2nd ed](#)

22 January 2024

[Workshop on malaria surveillance and malaria elimination in the Greater Mekong Subregion, Siem Reap,...](#)

.....

.....

USA – HHS, FDA, CDC

HHS

News

[Readout of HHS Meeting with Health Care Providers on COVID-19 Therapeutics Commercialization](#)

January 23, 2024 *News Release*

FDA

Press Announcements

No new digest content identified.

FDA VRBPAC

Advisory Committee Calendar

No new meetings scheduled.

CDC/ACIP [U.S.] [to 27 Jan 2024]

<http://www.cdc.gov/media/index.html>

Latest News Releases

No new digest content identified.

ACIP Meetings

Next ACIP Meeting

February 28-29

MMWR Weekly

<https://www.cdc.gov/mmwr/index2023.html>

January 25, 2024 / No. 3

[PDF of this issue](#)

[Selected items]

- [Underuse of Antiviral Drugs to Prevent Progression to Severe COVID-19 — Veterans Health Administration, March–September 2022](#)

.....
.....

Europe

European Medicines Agency [EMA]

<https://www.ema.europa.eu/en/news>

News & Press Releases

[EMA to support establishment of the African Medicines Agency](#)

EMA will harness its unique experience in coordinating intra-regional medicines regulation to support the strengthening of the African regulatory network.

26 January 2024

[Meeting highlights from the Committee for Medicinal Products for Human Use \(CHMP\) 22-25 January 2024](#)

EMA's human medicines committee (CHMP) recommended three medicines for approval at its January 2024 meeting.

26 January 2024

.....

European Centre for Disease Prevention and Control

<https://www.ecdc.europa.eu/en>

News/Updates/Reports/Publications [Selected]

[Vaccination coverage in the EU/EEA during Autumn 2023 campaigns](#)

News - 26 Jan 2024

Scientific and technical publications

[Interim COVID-19 vaccination coverage in the EU/EEA during the 2023–24 season campaigns](#)

24 January 2024

.....

.....

Africa CDC [to 27 Jan 2024]

<http://www.africacdc.org/>

Press Releases, Statements [Selected]

Press Releases

[Africa CDC Support on Cholera Outbreak in Zambia](#)

26 January 2024

...Africa CDC will also offer support through the following interventions:

- Train and deploy 500 community health workers in Kanyama and Matara district to support RCCE and Social and Behavioural Change (SBC) interventions.
- Production of IEC materials, including 10,000 flyers and radio jingles in various local languages.
- Strengthening laboratory capacity for diagnostic and genomic sequencing.
- Training of 50 healthcare workers on sample collection and referral.
- Deploy 150 clinical management staff (doctors, clinical officers, nurses, laboratory technicians, environmental health technicians, and pharmacists).
- Procurement of medical supplies, including Oral Rehydration Salts (ORS) and disinfectants, and water quality monitoring.
- Strengthen cross-border surveillance to circumvent further spread control of the outbreak.

The Africa CDC Director General has reaffirmed Africa CDC's readiness to provide technical support to the ongoing response efforts to control and end the ongoing Cholera outbreak in Zambia and the Southern African region.

.....

.....

China CDC

<http://www.chinacdc.cn/en/>

National Health Commission of the People's Republic of China [to 27 Jan 2024]

<http://en.nhc.gov.cn/>

News

No new digest content identified.

National Medical Products Administration – PRC [to 27 Jan 2024]

<http://english.nmpa.gov.cn/>

News

No new digest content identified.

China CDC Weekly Reports: Current Volume (6)

2024-01-19 / No. 4

No new digest content identified.

.....
.....

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....
.....

Organization Announcements

Paul G. Allen Frontiers Group [to 27 Jan 2024]

<https://alleninstitute.org/news-press/>

News

[How your immune system changes over time](#)

01.24.2024

Study reveals a type of T cell that vanishes with age and time's toll on 'age-resistant' immune cells

BMGF - Gates Foundation [to 27 Jan 2024]

<https://www.gatesfoundation.org/ideas/media-center>

Press Releases and Statements

[Gates Foundation CEO calls on philanthropists to step up giving to save and improve millions of lives](#)

SEATTLE (January 24, 2024) – In his [annual letter published today](#), Bill & Melinda Gates Foundation CEO [Mark Suzman](#) called for philanthropists to give more and give now to meet the unprecedented challenges nations across the globe face in combatting poverty, eradicating disease, and fighting inequality...

Bill & Melinda Gates Medical Research Institute [to 27 Jan 2024]

<https://www.gatesmri.org/news>

The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people

News: Articles and Publications

No new digest content identified.

CARB-X [to 27 Jan 2024]

<https://carb-x.org/>

News

No new digest content identified.

CEPI – Coalition for Epidemic Preparedness Innovations [to 27 Jan 2024]

<http://cepi.net/>

Latest News

Promising new 'circRNA' vaccines explored in CEPI-HMRI collaboration

New funding will develop a promising type of disease-defence technology that could pave the way for mRNA vaccines that are more stable, durable and cost-effective.

News 25 Jan 2024

Serum Institute of India joins CEPI global network to boost production of affordable outbreak vaccines

Capability expansion will support rapid development of outbreak vaccines for use in Global South countries when faced with a future 'Disease X'

End Pandemics 23 Jan 2024

CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES [to 27 Jan 2024]

<https://cioms.ch/>

News; Publications; Events

No new digest content identified.

DARPA – Defense Advanced Research Projects Agency [U.S.] [to 27 Jan 2024]

<https://www.darpa.mil/news>

News

1/24/2024

Establishing Qualification Processes for Point-of-Need Pharmaceutical Products

DARPA's new Establishing Qualification Processes for Agile Pharmaceutical Manufacturing (EQUIP-A-Pharma) program seeks to demonstrate a real-time digital regulatory approval framework for multiple finished drug products produced on a single reprogrammable hardware platform. The program aims to support up to four pilot agile pharmaceutical manufacturing sites that will generate the data required to inform the creation of a future regulatory framework.

Duke Global Health Innovation Center [to 27 Jan 2024]

<https://dukeghic.org/>

News

No new digest content identified.

EDCTP [to 27 Jan 2024]

<http://www.edctp.org/>

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials

News

No new digest content identified.

Emory Vaccine Center [to 27 Jan 2024]

<http://www.vaccines.emory.edu/>

Vaccine Center News

No new digest content identified.

European Vaccine Initiative [to 27 Jan 2024]

<http://www.euvaccine.eu/>

Latest News, Events

No new digest content identified.

Evidence Aid [to 27 Jan 2024]

Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use.

<http://www.evidenceaid.org/>

Resources [Selected]

No new digest content identified.

Fondation Merieux [to 27 Jan 2024]

<http://www.fondation-merieux.org/>

News, Events

No new digest content identified.

Gavi [to 27 Jan 2024]

<https://www.gavi.org/>

News Releases

No new digest content identified.

GE2P2 Global Foundation [to 27 Jan 2024]

www.ge2p2.org

News/Analysis/Publications-Digests/Statements

:: [Vaccines and Global Health: The Week in Review](#) - Current edition

:: [Informed Consent: A Monthly Review – January 2024](#)

:: [Genomic Medicine – Governance, Ethics, Policy, Practice: A Monthly Digest](#) – Oct 2023

:: [Public Consultations Watch :: Global Calls for Input/Public Comment – 09 January 2024 – Issue 12](#)

GHIT Fund [to 27 Jan 2024]

<https://www.ghitfund.org/newsroom/press>

Press Releases

No new digest content identified.

Global Fund [to 27 Jan 2024].

<https://www.theglobalfund.org/en/news/>

News & Stories

No new digest content identified.

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 27 Jan 2024]

<https://www.glopid-r.org/news/>

News

No new digest content identified.

Hilleman Laboratories [to 27 Jan 2024]

<http://www.hilleman-labs.org/>

News & Insights

No new digest content identified.

HHMI - Howard Hughes Medical Institute [to 27 Jan 2024]

<https://www.hhmi.org/news>

Press Room

No new digest content identified.

Human Immunome Project [nee Human Vaccines Project] [to 27 Jan 2024]

<http://www.humanvaccinesproject.org/>

News

No new digest content identified.

IAVI [to 27 Jan 2024]

<https://www.iavi.org/>

News, Features

Press Release

[ReiThera Srl, the Ragon Institute and IAVI announce collaboration to advance highly networked T-cell HIV vaccine candidate towards Phase I clinical evaluation](#)

January, 22 2024

INSERM [to 27 Jan 2024]

<https://www.inserm.fr/en/home/>

Press Releases

No new digest content identified.

International Coalition of Medicines Regulatory Authorities [ICMRA]

<http://www.icmra.info/drupal/en/news>

Selected Statements, Press Releases, Research

No new digest content identified.

ICH - International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use [to 27 Jan 2024]

<https://www.ich.org/page/press-releases>

News/Pubs/Press Releases [Selective]

No new digest content identified.

ICRC [to 27 Jan 2024]

<https://www.icrc.org/en/whats-new>

What's New [Selected]

[Gaza at risk of complete medical shut down without urgent action to preserve services](#)

Concrete actions must be taken to preserve access to life-saving and emergency medical care in the Gaza Strip, the International Committee of the Red Cross (ICRC) said Thursday.

24-01-2024 | News release

[The protection of the civilian population during sieges: what the law says](#)

The history of warfare is full of instances of sieges being used as a method of warfare. Some of them are notorious for their exceedingly high death tolls.

23-01-2024 | Article

IFFIm

<http://www.iffim.org/>

Press Releases/Announcements

No new digest content identified.

IFRC [to 27 Jan 2024]

<http://media.ifrc.org/ifrc/news/press-releases/>

Press Releases [Selected]

No new digest content identified.

Institut Pasteur [to 27 Jan 2024]

<https://www.pasteur.fr/en/press-area>

Press Documents

No new digest content identified.

ISC / International Science Council [to 27 Jan 2024]

<https://council.science/current/>

ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.

Latest Updates

Blogs

[Assessing the support offered to displaced Ukrainian scientists](#)

A new report by #ScienceForUkraine quantifies and assesses the adequacy of the support mechanisms in meeting the needs of displaced Ukrainian scientists. The study also explores implications for policymakers and scientific institutions for the effective design and implementation of support programmes aimed at scientists in times of crisis.

26.01.2024

Blogs

[Kigali Declaration: Climate science for a sustainable future for all](#)

Last October, climate scientists convened in Kigali, Rwanda, for the World Climate Research Programme (WCRP) Open Science Conference. The outcome was the Kigali Declaration, a powerful call for greater ambition and urgent action to address climate change.
25.01.2024

International Union of Immunological Societies (IUIS)

<https://iuis.org/>

News/Events [Selected]

No new digest content identified.

IVAC [to 27 Jan 2024]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

Updates; Events

No new digest content identified.

IVI [to 27 Jan 2024]

<http://www.ivi.int/>

IVI News & Announcements

No new digest content identified.

Johns Hopkins Center for Health Security [to 27 Jan 2024]

<https://centerforhealthsecurity.org/newsroom>

Center News [Selected]

January 22:

[**WHO renames Johns Hopkins Center for Health Security as Collaborating Centre for Global Health Security**](#)

MSF/Médecins Sans Frontières [to 27 Jan 2024]

<http://www.msf.org/>

Latest [Selected Announcements]

Gaza-Israel war

[**With Nasser hospital out of commission, people in southern Gaza run out of healthcare options**](#)

Press Release 26 Jan 2024

Nigeria

[**Tackling the spread of Lassa fever in Nigeria**](#)

Project Update 25 Jan 2024

National Academy of Medicine - USA [to 27 Jan 2024]

<https://nam.edu/programs/>

News [Selected]

[**100 Days Mission Shares New Report Highlighting Recommendations for Pandemic Preparedness**](#)

January 24, 2024

Today the International Pandemic Preparedness Secretariat launched the third annual report on the 100 Days Mission for pandemic preparedness at the Accademia dei Lincei in Rome. The report assesses international [...]

National Academy of Sciences - USA [to 27 Jan 2024]

<https://www.nationalacademies.org/newsroom?>

News

January 24, 2024

[Nancy Hopkins to Receive Public Welfare Medal – Academy's Most Prestigious Award](#)

WASHINGTON — The National Academy of Sciences is presenting its 2024 [Public Welfare Medal](#) to molecular biologist and women's equality advocate [Nancy Hopkins](#) for her courageous leadership over three decades to create and ensure equal opportunity for women in science. The medal is the Academy's most prestigious award, established in 1914 and presented annually to honor extraordinary use of science for the public good...

National Vaccine Program Office - U.S. HHS [to 27 Jan 2024]

<https://www.hhs.gov/vaccines/about/index.html>

Upcoming Meetings/Latest Updates

February 22-23, 2024 (Virtual)

NIH [to 27 Jan 2024]

<http://www.nih.gov/>

News Releases

No new digest content identified.

PATH [to 27 Jan 2024]

<https://www.path.org/media-center/>

Newsroom

No new digest content identified.

Rockefeller Foundation [to 27 Jan 2024]

<https://www.rockefellerfoundation.org/>

Press Releases and Speeches

No new digest content identified.

Sabin Vaccine Institute [to 27 Jan 2024]

<https://www.sabin.org/press/>

Latest News & Press Releases

No new digest content identified.

UNAIDS [to 27 Jan 2024]

<http://www.unaids.org/en>

Selected Press Releases/Reports/Statements

Press statement

[UNAIDS welcomes Jamaica's expansion of protections against gender-based violence](#)

Domestic Violence (Amendment) Act 2023 to Protect Women, Girls, Boys, and Men comes into effect

GENEVA, 22 January 2024

UNICEF [to 27 Jan 2024]

<https://www.unicef.org/media/press-releases>

Latest press releases, news notes and statements

No new digest content identified.

Unitaid [to 27 Jan 2024]

<https://unitaid.org/>

Featured News

No new digest content identified.

Vaccine Equity Cooperative [nee Initiative] [to 27 Jan 2024]

<https://vaccineequitycooperative.org/news/>

News

No new digest content identified.

Vaccination Acceptance & Demand Initiative [Sabin] [to 27 Jan 2024]

<https://www.vaccineacceptance.org/>

Announcements, Blog

No new digest content identified.

Vaccine Confidence Project [to 27 Jan 2024]

<http://www.vaccineconfidence.org/>

News, Research and Reports

No new digest content identified.

Vaccine Education Center – Children’s Hospital of Philadelphia [to 27 Jan 2024]

<http://www.chop.edu/centers-programs/vaccine-education-center>

News

No new digest content identified.

Wellcome Trust [to 27 Jan 2024]

<https://wellcome.org/>

News, Opinion, Reports

News

[We’re launching targeted funding for researchers of Black, Bangladeshi and Pakistani heritage in the UK](#)

24 January 2024 5-minute read

Wellcome is launching £20 million in new funding. This is to support researchers of Black, Bangladeshi and Pakistani heritage in the UK to stay in research and advance their careers.

The Wistar Institute [to 27 Jan 2024]
<https://www.wistar.org/news/press-releases>
Press Releases
No new digest content identified.

World Bank [to 015 Oct 2022]
<http://www.worldbank.org/en/news/all>
All News [Selected]
No new digest content identified.

WFPHA: World Federation of Public Health Associations [to 27 Jan 2024]
<https://www.wfpha.org/>
No new digest content identified.

World Medical Association [WMA] [to 27 Jan 2024]
<https://www.wma.net/news-press/press-releases/>
Press Releases

Declaration of Helsinki – Phase I Public Comment Period

In order to maximize input by all stakeholders and the public, we are providing two separate public comment periods. A phase 1 public comment period is being held now to address issues from the first few regional meetings, and a phase 2 comment period will follow in the spring when additional topics have been addressed.

Open Now: Phase 1 Public Comment Period Due: 7 February 2024.

The workgroup's proposed edits to date are now available for public comment. To submit your or your organization's feedback, download the [phase 1 public comment document](#)

World Organisation for Animal Health [to 27 Jan 2024]
<https://www.oie.int/en/>
Press Releases, Statements
100th Anniversary, Press Release

The World Organisation for Animal Health turns 100: A century of improving animal health and welfare

Paris (France), 25 January 2024 - The World Organisation for Animal Health (WOAH) proudly commemorates 100 years of unwavering commitment and its achievements in advancing animal health and welfare worldwide. The journey leading up to WOAH becoming the global authority on animal health is marked by a long history of pivotal moments.

.....

ARM [Alliance for Regenerative Medicine] [to 27 Jan 2024]
<https://alliancerm.org/press-releases/>
Selected Press Releases
No new digest content identified.

BIO [to 27 Jan 2024]
<https://www.bio.org/press-releases>
Press Releases

[New BIO Report Finds More Innovation & Investment Needed in Vaccine Development](#)

January 25, 2024

Today, the Biotechnology Innovation Organization (BIO) released a new report, "The State of Innovation in Vaccines and Prophylactic Antibodies for Infectious Diseases," examining the latest scientific and investment trends in vaccine development...

DCVMN – Developing Country Vaccine Manufacturers Network [to 27 Jan 2024]

<http://www.dcvmn.org/>

News; Upcoming events

No new digest content identified.

ICBA – International Council of Biotechnology Associations [to 27 Jan 2024]

<https://internationalbiotech.org/news/>

News

No new digest content identified.

IFPMA [to 27 Jan 2024]

<https://ifpma.org/>

Selected Press Releases/Statements

Statement 26 Jan 2024

[EB154 individual statement on antimicrobial resistance \(AMR\)](#)

On 24 January, IFPMA delivered a statement on antimicrobial resistance (AMR) at the WHO 154th Executive Board in Geneva, Switzerland.

Statement 25 Jan 2024

[EB154 individual statement on health emergencies](#)

On 25 January, IFPMA delivered a statement on health emergencies at the WHO 154th Executive Board in Geneva, Switzerland.

Statement 24 Jan 2024

[EB154 constituency statement on non-communicable diseases](#)

On 24 January, IFPMA, GSCF, and IGBA delivered a joint constituency statement on non-communicable diseases and Universal Health Coverage (UHC) at the WHO 154th Executive Board in Geneva, Switzerland.

International Alliance of Patients' Organizations – IAPO [to 27 Jan 2024]

<https://www.iapo.org.uk/news>

Press and media [Selected]

No new digest announcements identified

International Generic and Biosimilar Medicines Association [IGBA]

<https://www.igbamedicines.org/>

News

[Joint Industry Statement for WHO's Executive Board Meeting 154 \(January 2024\)](#)

We welcome the Executive Board (EB) report on noncommunicable diseases (NCDs) and WHO's continued efforts to tackle one of the greatest health challenges of our lifetimes. With childhood obesity and diabetes on an alarming rise, alongside population ageing, urbanization, climate change,

air pollution amongst other factors, a life-course approach to tackling NCDs is critical given the unsustainable pressures chronic conditions and comorbidities are placing on healthcare systems worldwide.

PhRMA [to 27 Jan 2024]

<http://www.phrma.org/>

Press Releases

No new digest announcements identified.

.....
.....

Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements

AstraZeneca

Press Releases - *No new digest announcements identified.*

Bharat Biotech

Press Releases - *No new digest announcements identified.*

BioCubaFarma – Cuba

Últimas Noticias - *No new digest announcements identified*

Biological E

News

BE's CORBEVAX GETS WHO EUL AUTHORIZATION

CORBEVAX is India's first indigenously developed RBD Protein Sub-unit Vaccine against COVID-19

CORBEVAX is India's first heterologous COVID-19 booster shot for adults 18 & above

Hyderabad, January 16, 2024: Biological E. Limited (BE), a Hyderabad-based Vaccines and Pharmaceutical company, today announced that the World Health Organisation (WHO) has granted an Emergency Use Listing (EUL) to their CORBEVAX vaccine, which is India's first indigenously developed COVID-19 vaccine that is based on protein sub-unit platform...

BioNTech

Press Releases

22 January 2024

BioNTech and DualityBio Initiate Pivotal Phase 3 Trial Of Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Metastatic Breast Cancer

Boehringer

Press Releases - *No new digest announcements identified.*

CanSinoBIO

News - *Website not responding at inquiry*

CIGB

Latest News - *No new digest announcements identified.*

Cinnagen

Recent News - *No new digest announcements identified.*

Clover Biopharmaceuticals - China

News - No new digest announcements identified.

Curevac [Bayer Ag – Germany]

News - No new digest announcements identified

Gamaleya National Center/Sputnik

Latest News and Events - No new digest announcements identified

<https://sputnikvaccine.com/> - No new digest announcements identified

GSK

Press releases for media - No new digest announcements identified

IMBCAMS, China

Home - Website not responding at inquiry.

Janssen/JNJ

Press Releases - No new digest announcements identified

Merck

News releases - No new digest announcements identified

Moderna

Press Releases - No new digest announcements identified

Nanogen

News - No new digest announcements identified

Novartis

News - No new digest announcements identified.

Novavax

Press Releases

Jan 24, 2024

COVID-19

[Novavax's Updated COVID-19 Vaccine Authorized in the United Kingdom](#)

Jan 23, 2024

Statement COVID-19

[Novavax's Updated Protein-based Non-mRNA COVID-19 Vaccine Available in Taiwan Vaccination Centers](#)

Pfizer

Recent Press Releases - No new digest announcements identified.

R-Pharm

<https://rpharm-us.com/index.php>

[No news or media page identified]

Sanofi Pasteur

Press Releases - No new digest announcements identified.

Serum Institute of India

NEWS & ANNOUNCEMENTS

Tuesday, January 23, 2024

[Serum Institute of India joins CEPI global network to boost production of affordable outbreak vaccines ...](#)

Sinopharm/WIBPBIBP

News - No new digest announcements identified [English translation function not operating]

Sinovac

Press Releases - No new digest announcements identified

SK Biosciences

Press Releases - No new digest announcements identified.

Takeda

Newsroom - No new digest announcements identified.

Valneva

Press Releases - No new digest announcements identified.

Vector State Research Centre of Virology and Biotechnology

Home - Website not responding [404 error]

WestVac Biopharma

Media - No new digest announcements identified.

Zhifei Longcom, China

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

Website [No News/Announcements page identified]

.....

.....

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....

.....

Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics

Volume 15, 2023 Issue 1

<https://www.tandfonline.com/toc/uabr21/current>

Article

[Comparing Attitudes About Genomic Privacy and Data Sharing in Adolescents and Parents of Children Enrolled in a Genomic Research Repository](#)

Courtney Berrios, Shelby Neal, Tricia Zion & Tomi Pastinen

Pages: 33-40 Published online: 24 Jul 2023

Article

[Toward Consent in Molecular HIV Surveillance?: Perspectives of Critical Stakeholders](#)

Stephen Molldrem, Anthony K J Smith & Vishnu Subrahmanyam

Pages: 66-79 Published online: 24 Jan 2024

AMA Journal of Ethics

Volume 26, Number 1: E1-96 Jan 2024

<https://journalofethics.ama-assn.org/issue/critical-pedagogies-health-professions-education>

Critical Pedagogies in Health Professions Education

Health professions training is mainly competency driven, with students' and trainees' learning and technical skill development regularly assessed, usually in terms of standardized outcomes. Yet, there are good ethical and clinical questions to ask about competency-based medical education, specifically about how schools' and academic health centers' curricula meaningfully motivate learning and skill development about social privilege, health equity, and structural determinants of patients' health and health outcomes. This theme issue considers whether and to what extent skill development about, for example, the affective features of, say, coming to terms with one's privilege is teachable and assessable in competency-based frameworks, especially when those frameworks have a history of excluding key perspectives. Critical pedagogies investigated herein suggest strategies for interrogating teaching and learning methods and curricular content that are socially, culturally, politically, and historically fraught.

American Journal of Human Genetics

Jan 04, 2024 Volume 111 Issue 1 p1-210

<https://www.cell.com/ajhg/current>

[This Month in The Journal](#)

Alyson B. Barnes, Kylee L. Spencer, Sara B. Cullinan

Biobanks are becoming increasingly common, and although each has its own goals, strengths, and challenges, the standard recipe is a focus on scientific discovery through genetic data linked to electronic health records (EHRs). In this issue, Wiley et al. describe the development of the Colorado Center for Personalized Medicine Biobank (CCPM Biobank), which is not only designed to advance research but also to directly impact patient care. A few key elements were crucial to achieving these dual aims.

[Reviewed earlier]

American Journal of Infection Control

January 2024 Volume 52 Issue 1 p1-140

<http://www.ajicjournal.org/current>

[Reviewed earlier]

American Journal of Preventive Medicine

January 2024 Volume 66 Issue 1 p1-194

<https://www.ajpmonline.org/current>

[Reviewed earlier]

American Journal of Public Health

January 2024 114(1)

<http://ajph.aphapublications.org/toc/ajph/current>

[Reviewed earlier]

American Journal of Tropical Medicine and Hygiene

Volume 110 (2024): Issue 1 (Jan 2024)

<https://www.ajtmh.org/view/journals/tpmd/110/1/tpmd.110.issue-1.xml>

[Reviewed earlier]

Annals of Internal Medicine

January 2024 Volume 177, Issue 1

<https://www.acpjournals.org/toc/aim/current>

Original Research

[HIV Testing and Preexposure Prophylaxis Prescriptions Among U.S. Commercially Insured Transgender Men and Women, 2014 to 2021](#)

Ya-Lin A. Huang, PhD, MS, Asa Radix, MD, PhD, MPH, Weiming Zhu, PhD, MD, [... et al.](#)

Pages:12–17

Ideas and Opinions

[An Ethical and Financial Obligation for Sickle Cell Disease Gene Therapy in the United States](#)

Austin Wesevich, MD, MPH, Monica E. Peek, MD, MPH, MSc, and Mark J. Ratain, MD

Pages:85–86

Artificial Intelligence – An International Journal

Volume 327 February 2024

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/327/suppl/C>

[Reviewed earlier]

BMC Cost Effectiveness and Resource Allocation

<http://resource-allocation.biomedcentral.com/>

(Accessed 27 Jan 2024)

[Reimagining the relationship between economics and health– WHO 'Health for all' provisions](#)

Authors: Stavros Petrou and Mihajlo Jakovljevic

Content type: Editorial 23 January 2024

BMC Health Services Research

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 27 Jan 2024)

[No new digest content identified]

BMC Infectious Diseases

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 27 Jan 2024)

[No new digest content identified]

BMC Medical Ethics

<http://www.biomedcentral.com/bmcmethics/content>

(Accessed 27 Jan 2024)

[Integrating ethics in AI development: a qualitative study](#)

Authors: Laura Arbelaez Ossa, Giorgia Lorenzini, Stephen R. Milford, David Shaw, Bernice S. Elger and Michael Rost

Content type: Research 23 January 2024

While the theoretical benefits and harms of Artificial Intelligence (AI) have been widely discussed in academic literature, empirical evidence remains elusive regarding the practical ethical challenges of developing AI for healthcare. Bridging the gap between theory and practice is an essential step in understanding how to ethically align AI for healthcare. Therefore, this research examines the concerns and challenges perceived by experts in developing ethical AI that addresses the healthcare context and needs.

BMC Medicine

<http://www.biomedcentral.com/bmcmmed/content>

(Accessed 27 Jan 2024)

[No new digest content identified]

BMC Pregnancy and Childbirth

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 27 Jan 2024)

[No new digest content identified]

BMC Public Health

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 27 Jan 2024)

[Relationship between religiosity and HPV vaccine initiation and intention in urban black and hispanic parents](#)

Religion is believed to be an important sociocultural influence in the U.S., but little is known about how religiosity shapes the human papillomavirus (HPV) vaccine decision in racial/ethnic minorities.

The pu...

Authors: Deidra Carroll Coleman, Christine Markham, Vincent Guilamo-Ramos and Diane Santa Maria

Citation: BMC Public Health 2024 24:265

Content type: Research Published on: 23 January 2024

BMC Research Notes

<http://www.biomedcentral.com/bmcresnotes/content>

(Accessed 27 Jan 2024)

[No new digest content identified]

BMJ Evidence-Based Medicine

February 2024 - Volume 29 - 1

<https://ebm.bmj.com/content/29/1>

[Reviewed earlier]

BMJ Global Health

January 2024 - Volume 9 - 1

<https://gh.bmj.com/content/9/1>

[Reviewed earlier]

Bulletin of the Atomic Scientists

January 2024

<https://thebulletin.org/magazine/2024-01/>

[Reviewed earlier]

Bulletin of the World Health Organization

Volume 102(1); 2024 Jan 1

<https://www.ncbi.nlm.nih.gov/pmc/issues/451803/>

[New issue; No digest content identified]

Cell

Jan 18, 2024 Volume 187 Issue 2 p217-510

<https://www.cell.com/cell/current>

[New issue; No digest content identified]

Child Care, Health and Development

Volume 50, Issue 1 January 2024

<https://onlinelibrary.wiley.com/toc/13652214/current>

[Reviewed earlier]

Clinical Pharmacology & Therapeutics

Volume 115, Issue 1 Pages: 1-157 January 2024

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

[Reviewed earlier]

Clinical Therapeutics

January 2024 Volume 46 Issue 1 p1-84

<http://www.clinicaltherapeutics.com/current>

[Reviewed earlier]

Clinical Trials

Volume 20 Issue 6, December 2023

<https://journals.sagepub.com/toc/ctja/20/6>

[Reviewed earlier]

Conflict and Health

<http://www.conflictandhealth.com/>

[Accessed 27 Jan 2024]

[No new digest content identified]

Contemporary Clinical Trials

Volume 135 December 2023

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/135/suppl/C>

[Reviewed earlier]

The CRISPR Journal

Volume 6, Issue 6 / December 2023

<https://www.liebertpub.com/toc/crispr/6/6>

[Reviewed earlier]

Current Genetic Medicine Reports

Volume 11, issue 1-2, June 2023

<https://link.springer.com/journal/40142/volumes-and-issues/11-1>

[Reviewed earlier]

Current Medical Research and Opinion

Volume 40, Issue 1 2024

<https://www.tandfonline.com/toc/icmo20/current>

[Reviewed earlier]

Current Opinion in Infectious Diseases

February 2024 - Volume 37 - Issue 1

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

[Reviewed earlier]

Current Protocols in Human Genetics

<https://currentprotocols.onlinelibrary.wiley.com/journal/19348258>

[Accessed 27 Jan 2024]

[No new digest content identified]

Developing World Bioethics

Volume 23, Issue 4 Pages: 293-377 December 2023

<https://onlinelibrary.wiley.com/toc/14718847/current>

ORIGINAL ARTICLES

[Reviewed earlier]

Development in Practice

Volume 33, Issue 8, 2023

<http://www.tandfonline.com/toc/cdip20/current>

[Reviewed earlier]

Development Policy Review

Volume 42, Issue 1 January 2024

<https://onlinelibrary.wiley.com/toc/14677679/current>

[Reviewed earlier]

Disaster Medicine and Public Health Preparedness

Volume 17 - 2024

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[Reviewed earlier]

Disasters

Volume 47, Issue 4 Pages: 847-1173 October 2023

<https://onlinelibrary.wiley.com/toc/14677717/2023/47/4>

[Reviewed earlier]

EMBO Reports

Volume 25 Issue 1 12 January 2024

<https://www.embopress.org/toc/14693178/current>

[New issue; No digest content identified]

Emerging Infectious Diseases

Volume 29, Number 12—December 2023

<http://wwwnc.cdc.gov/eid/>

[New issue; No digest content identified]

Epidemics

Volume 45 December 2023

<https://www.sciencedirect.com/journal/epidemics/vol/45/suppl/C>

[Reviewed earlier]

Epidemiology and Infection

Volume 152 - 2024

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

Ethics & Human Research

Volume 46, Issue 1 Pages: 1-48 January–February 2024

<https://onlinelibrary.wiley.com/toc/25782363/current>

• *Local context and emergency research* • *Participant fraud in online research*
Passing demands in autism research :: Women missing in phase I trials

[Reviewed earlier]

Ethics & International Affairs

Volume 37 - Issue 4 - Winter 2023

<https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue>

[Reviewed earlier]

Ethics, Medicine and Public Health

Volume 31 (December 2023)

<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/31/suppl/C>

[Reviewed earlier]

The European Journal of Public Health

Volume 33, Issue 6, December 2023

<https://academic.oup.com/eurpub/issue/33/6>

[Reviewed earlier]

Expert Review of Vaccines

Vol 22 (1) 2023

<https://www.tandfonline.com/toc/ierv20/current>

[Reviewed earlier]

Foreign Affairs

January/February 2024 Volume 103, Number 1

<https://www.foreignaffairs.com/issues/2023/103/1>

[Reviewed earlier]

Forum for Development Studies

Volume 50, 2023 - Issue 3

<http://www.tandfonline.com/toc/sfds20/current>

[Reviewed earlier]

Genetics in Medicines

Volume 26, Issue 1 January 2024

<https://www.sciencedirect.com/journal/genetics-in-medicine/vol/25/issue/12>

[Reviewed earlier]

Genome Medicine

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 27 Jan 2024]

[No new digest content identified]

Global Health Action

Volume 17, Issue 1 (2024)

<https://www.tandfonline.com/toc/zgha20/current?nav=toclist>

[Reviewed earlier]

Global Health: Science and Practice (GHSP)

Vol. 11, No. 6 December 22, 2023

<http://www.ghspjournal.org/content/current>

[Reviewed earlier]

Global Legal Monitor & Legal Reports – Library of Congress/USA

<https://www.loc.gov/collections/global-legal-monitor/>

https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date_desc

[Accessed 27 Jan 2024]

[No new digest content identified]

Global Public Health

Volume 19, Issue 1 (2024)

<http://www.tandfonline.com/toc/rgph20/current>

[Reviewed earlier]

Globalization and Health

<http://www.globalizationandhealth.com/>

[Accessed 27 Jan 2024]

[No new digest content identified]

Health and Human Rights

Volume 25, Issue 2, December 2023

<https://www.hhrjournal.org/volume-25-issue-2-december-2023/>

Special Section: Economic Inequality and the Right to Health

[Reviewed earlier]

Health Economics, Policy and Law

Volume 18 - Special Issue 4 - October 2023

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

SPECIAL ISSUE: On the roof top of health policy change

[Reviewed earlier]

Health Policy and Planning

Volume 38, Issue 10, December 2023

<https://academic.oup.com/heapol/issue/38/10>

[Reviewed earlier]

Health Research Policy and Systems

<http://www.health-policy-systems.com/content>

[Accessed 27 Jan 2024]

[No new digest content identified]

Human Gene Therapy

Volume 35, Issue 1-2 / January 2024

<https://www.liebertpub.com/toc/hum/35/1-2>

Review

[Advancing Precision Medicine with Gene and Cell Therapy in Malaysia: Ethical, Legal, and Social Implications](#)

V. Kalidasan and [Kumitaa Theva Das](#)

Pages:9–25

Published Online:4 December 2023

<https://doi.org/10.1089/hum.2023.139>

Humanitarian Practice Network

<https://odihpn.org/>

Featured Publications

[No new digest content identified]

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)

Volume 19, Issue 3, 2023

<https://www.tandfonline.com/toc/khvi20/19/3?nav=tocList>

[Reviewed earlier]

Immunity

Jan 09, 2024 Volume 57 Issue 1 p1-192

<https://www.cell.com/immunity/current>

Resource

[Multi-omics analysis of innate and adaptive responses to BCG vaccination reveals epigenetic cell states that predict trained immunity](#)

Simone J.C.F.M. Moorlag, et al.

Open Access

The response to vaccination and immune stimuli varies widely between individuals. To dissect population variation in immune function, Moorlag, Folkman, ter Horst, Krausgruber, et al. perform multi-omics analysis before and after BCG vaccination. They find that trained immunity induction is most effective in individuals with a dormant immune state at baseline.

Infectious Agents and Cancer

<http://www.infectagentscancer.com/>

[Accessed 27 Jan 2024]

[No new digest content identified]

Infectious Diseases of Poverty

<http://www.idpjournal.com/content>

[Accessed 27 Jan 2024]

[No new digest content identified]

International Health

Volume 15, Issue 6, November 2023

<https://academic.oup.com/inthealth/issue/15/6>

[Reviewed earlier]

International Human Rights Law Review

Volume 12 (2023): Issue 2 (Dec 2023)

<https://brill.com/view/journals/hrlr/12/2/hrlr.12.issue-1.xml>

Table of Contents

[Reviewed earlier]

International Journal of Community Medicine and Public Health

Vol. 11 No. 1 (2024): January 2024

<https://www.ijcmph.com/index.php/ijcmph/issue/view/108>

Review Articles

[**The pandemic and Africa: a review of the psychological, social, and nutritional impact of COVID-19 in Africa**](#)

Calvin R. Wei, Chenyue Fan, Maria Rizwan, Godwin C. Lang'at, Malachy B. Peter

566-576

DOI: [10.18203/2394-6040.ijcmph20234158](https://doi.org/10.18203/2394-6040.ijcmph20234158)

International Journal of Epidemiology

Volume 52, Issue 6, December 2023

<https://academic.oup.com/ije/issue>

[Reviewed earlier]

International Journal of Human Rights in Healthcare

Volume 16 Issue 3 2023

<https://www.emerald.com/insight/publication/issn/2056-4902/vol/16/iss/3>

Table of contents

[Reviewed earlier]

JAMA

January 23/30, 2024, Vol 331, No. 4, Pages 271-368

<https://jamanetwork.com/journals/jama/currentissue>

Viewpoint

[Is Vaccination Approaching a Dangerous Tipping Point?](#)

Peter Marks, MD, PhD; Robert Califf, MD

free access

JAMA. 2024;331(4):283-284. doi:10.1001/jama.2023.27685

This Viewpoint discusses declining vaccination rates in the US, specifically against COVID-19, and the ways in which clinicians and the Food and Drug Administration can counter the current large volume of vaccine misinformation.

JAMA Health Forum

January 2024, Vol 5, No. 1

<https://jamanetwork.com/journals/jama-health-forum/issue>

[Reviewed earlier]

JAMA Pediatrics

January 2024, Vol 5, No. 1

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

[Reviewed earlier]

JBI Evidence Synthesis

January 2024 - Volume 22 - Issue 1

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

Protocols

[Cost-effectiveness of a decentralized care model for managing multi-drug-resistant tuberculosis in low- and middle-income countries: a systematic review protocol](#)

Mahapatra, Biswajit; Bhattacharya, Paramita; Karuveetil, Vineetha; More

JBI Evidence Synthesis. 22(1):97-105, January 2024.

Journal of Adolescent Health

January 2024 Volume 74 Issue 1 p1-212

<https://www.jahonline.org/current>

[Reviewed earlier]

Journal of Artificial Intelligence Research

Vol. 78 (2023)

<https://www.jair.org/index.php/jair>

Contents

[Reviewed earlier]

Journal of Community Health

Volume 48, issue 6, December 2023

<https://link.springer.com/journal/10900/volumes-and-issues/48-6>

[Reviewed earlier]

Journal of Current Medical Research and Opinion

...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.

Vol. 7 No. 01 (2024), January 2, 2024 , Page 1988-1996

<https://www.cmro.in/index.php/jcmro/issue/view/75>

[New issue; No digest content identified]

Journal of Development Economics

Volume 166 January 2024

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/166/suppl/C>

[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics

Volume 18 Issue 5, December 2023

<http://journals.sagepub.com/toc/jre/current>

[Reviewed earlier]

Journal of Epidemiology & Community Health

January 2024 - Volume 78 - 1

<https://jech.bmj.com/content/78/1>

[Reviewed earlier]

Journal of Evidence-Based Medicine

Volume 16, Issue 4 Pages: 415-580 December 2023

<https://onlinelibrary.wiley.com/toc/17565391/current>

[Reviewed earlier]

Journal of Global Ethics

Volume 19, Issue 3 (2023)

<http://www.tandfonline.com/toc/rjge20/current>

[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)

Volume 34, Number 4, November 2023

<https://muse.jhu.edu/issue/51329>

Table of Contents

[Reviewed earlier]

Journal of Immigrant and Minority Health

Volume 25, issue 6, December 2023

<https://link.springer.com/journal/10903/volumes-and-issues/25-6>

[Reviewed earlier]

Journal of Immigrant & Refugee Studies

Volume 21, 2023 _ Issue 4

<https://www.tandfonline.com/toc/wimm20/current>

Towards a New Migration and Asylum Research Agenda for the Americas

Journal of Infectious Diseases

Volume 228, Issue 12, 15 December 2023

<https://academic.oup.com/jid/issue/228/12>

[Reviewed earlier]

Journal of International Development

Volume 36, Issue 1 Pages: 1-772 January 2024

<https://onlinelibrary.wiley.com/toc/10991328/current>

[Reviewed earlier]

Journal of Medical Ethics

January 2024 - Volume 50 - 1

<http://jme.bmj.com/content/current>

[Reviewed earlier]

Journal of Patient-Centered Research and Reviews

Volume 10, Issue 4 (2023)

<https://institutionalrepository.aah.org/jpcrr/>

[Reviewed earlier]

The Journal of Pediatrics

Volume 264 January 2024

<https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/264/suppl/C>

[Reviewed earlier]

Journal of Pharmaceutical Policy and Practice

Volume 17, Issue 1 (2024) Issue 1

<https://www.tandfonline.com/toc/jppp20/17/1>

[Reviewed earlier]

Journal of Public Health Management & Practice

January/February 2024 - Volume 30 - Issue 1

<https://journals.lww.com/jphmp/pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Public Health Policy

Volume 44, issue 4, December 2023

<https://link.springer.com/journal/41271/volumes-and-issues/44-4>

[New issue; No digest content identified]

Journal of the Royal Society – Interface

January 2024 Volume 21 Issue 210

<https://royalsocietypublishing.org/toc/rsif/current>

[Reviewed earlier]

Journal of Travel Medicine

Volume 30, Issue 8, December 2023

<https://academic.oup.com/jtm/issue>

[Reviewed earlier]

Journal of Virology

Volume 97 • Number 12 • December 2023

<http://jvi.asm.org/content/current>

[Reviewed earlier]

The Lancet

Jan 27, 2024 Volume 403 Number 10424 p325-408

<https://www.thelancet.com/journals/lancet/issue/current>

Editorial

[Economic storms threaten to cast health adrift](#)

The Lancet

Is anyone listening to the World Bank's Chief Economist? Many countries, says Indermit Gill, are “on a path to crisis”. The poorest countries are “stuck in a trap” that threatens to “obstruct progress on many global priorities”. “Without a major course correction, the 2020s will go down as a decade of wasted opportunity.” Gill's main concern, as outlined in a series of World Bank reports, is the paralysing amount of debt, exacerbated by soaring interest rates, faced by many low-income and middle-income countries (LMICs). As governments struggle to service their debt obligations, spending on public services, such as health and education, is likely to be slashed. Gill's comments are a dire warning of difficulties ahead for the global health community. How should countries respond?...

The obvious international response is debt relief. The Bridgetown Initiative is a proposal by Mia Mottley, Prime Minister of Barbados, to reform the international financial system. Mottley recommends giving countries immediate liquidity support, low-interest debt restructuring, drastically increased development lending, and private sector green investment. She also called for more representative and equitable financial governance and a more just trade system. Her ideas will feed into this year's Summit of the Future in September and next year's Finance for Development Conference. However, the acute threat facing countries cannot await this pedestrian timetable. With wars and imminent elections distracting many world leaders, prospects for action seem bleak. But countries need to invest in their people, and many require debt relief to do so effectively. To ignore Gill's warnings risks devastating human consequences.

The Lancet Child & Adolescent Health

Jan 2024 Volume 8 Number 1 p1-84

<https://www.thelancet.com/journals/lanchi/issue/current>

[Reviewed earlier]

Lancet Digital Health

Jan 2024 Volume 6 Number 1 e1-e86

<https://www.thelancet.com/journals/landig/issue/current>

[Reviewed earlier]

Lancet Global Health

Jan 2024 Volume 12 Number 1 e1-e169

<https://www.thelancet.com/journals/langlo/issue/current>

[Reviewed earlier]

Lancet Infectious Diseases

Jan 2024 Volume 24 Number 1 p1-106, e1-e69

<https://www.thelancet.com/journals/laninf/issue/current>

[Reviewed earlier]

Lancet Public Health

Jan 2024 Volume 9 Number 1 e1-e67

<https://www.thelancet.com/journals/lanpub/issue/current>

[New issue; No digest content identified]

Lancet Respiratory Medicine

Jan 2024 Volume 12 Number 1 p1-88

<https://www.thelancet.com/journals/lanres/issue/current>

[Reviewed earlier]

Maternal and Child Health Journal

Volume 27, issue 12, December 2023

<https://link.springer.com/journal/10995/volumes-and-issues/27-12>

[Reviewed earlier]

Medical Decision Making (MDM)

Volume 101, Issue 4 Pages: 999-1374 December 2023

<http://mdm.sagepub.com/content/current>

[Reviewed earlier]

The Milbank Quarterly

A Multidisciplinary Journal of Population Health and Health Policy

Volume 101, Issue 3 Pages: 637-998 September 2023

<https://onlinelibrary.wiley.com/toc/14680009/current>

[Reviewed earlier]

Molecular Therapy

Jan 03, 2024 Volume 32 Issue 1 p1-260

<https://www.cell.com/molecular-therapy/current>

[Reviewed earlier]

Nature

Volume 625 Issue 7996, 25 January 2024

<https://www.nature.com/nature/volumes/625/issues/7995>

[New issue; No digest content identified]

Nature Biotechnology

Volume 42 Issue 1, January 2024

<https://www.nature.com/nbt/volumes/42/issues/1>

[Reviewed earlier]

Nature Communications

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 27 Jan 2024)

[No new digest content identified]

Nature Genetics

Volume 56 Issue 1, January 2024

<https://www.nature.com/ng/volumes/56/issues/1>

Editorial 02 Jan 2024

[A call for spatial omics submissions](#)

The field of spatial omics is developing rapidly, with a potentially transformative effect across many areas of biology. Nature Genetics invites authors to submit papers that use these techniques to answer questions of broad interest to researchers working in genetics and genomics.

Nature Human Behaviour

Volume 7 Issue 12, December 2023

<https://www.nature.com/nathumbehav/volumes/7/issues/12>

Moral reasoning in the brain

[Reviewed earlier]

Nature Medicine

Volume 30 Issue 1, January 2024

<https://www.nature.com/nm/volumes/30/issues/1>

Editorial 19 Jan 2024

[A life-course approach to women's health](#)

We are launching a new Series as a starting point for discussions on how to improve the health of women and girls as part of a route to achieving global health equity.

Comment 04 Jan 2024

[A society-wide conversation is needed about germline genome editing using CRISPR](#)

Therapeutic genome editing has great potential to cure some rare diseases, but germline editing is banned. With a broad societal discussion supported by national and transnational legislation, it could be allowed in certain circumstances.

Ewan Birney

Nature Reviews Drug Discovery

Volume 23 Issue 1, January 2024

<https://www.nature.com/nrd/volumes/23/issues/1>

COMMENT 29 November 2023

[A call to adapt the regulation of HLA testing for T cell receptor-based therapeutics](#)

Current regulation of T cell receptor (TCR)-based therapeutics may require repeated testing of patients for specific HLA alleles as well as companion diagnostics development, despite the invariant nature of the HLA genotype and availability of robust clinical HLA tests. This increases the burden on patients and the organizations developing these products. We propose regulatory flexibility to facilitate the development of and access to TCR-based therapeutics.

By [Miriam Meyer](#), et al.

Review Article 29 Nov 2023

[Tailor made: the art of therapeutic mRNA design](#)

The recent success of mRNA vaccines has boosted the prospects for the development of a new class of designer medicines based on mRNA. This Review discusses the multiple design parameters that need to be carefully considered to create highly effective mRNA medicines.

Mihir Metkar, Christopher S. Pepin, Melissa J. Moore

Nature Reviews Genetics

Volume 25 Issue 1, January 2024

<https://www.nature.com/nrg/volumes/25/issues/1>

[Reviewed earlier]

Nature Reviews Immunology

Volume 24 Issue 1, January 2024

<https://www.nature.com/nri/volumes/24/issues/1>

[New issue; No digest content identified]

New England Journal of Medicine

January 25, 2024 Vol. 390 No. 4

<https://www.nejm.org/toc/nejm/medical-journal>

[New issue; No digest content identified]

njp Vaccines

<https://www.nature.com/npjvaccines/>

[Accessed 27 Jan 2024]

[No new digest content identified]

Pediatrics

Volume 153, Issue 1 January 2024

<https://publications.aap.org/pediatrics/issue/152/4>

[Reviewed earlier]

Pharmacoeconomics

Volume 41, Issue 12 December 2023

<https://link.springer.com/journal/40273/volumes-and-issues/41-12>

[Reviewed earlier]

PLoS Biology

<https://journals.plos.org/plosbiology/>

(Accessed 27 Jan 2024)

[No new digest content identified]

PLoS Genetics

<https://journals.plos.org/plosgenetics/>

(Accessed 27 Jan 2024)

[No new digest content identified]

PLoS Global Public Health

https://journals.plos.org/globalpublichealth/search?sortOrder=DATE_NEWEST_FIRST&filterStartDate=2021-10-01&filterJournals=PLOGlobalPublicHealth&q=&resultsPerPage=60

(Accessed 27 Jan 2024)

[**Impact of the COVID-19 pandemic and policy response on access to and utilization of reproductive, maternal, child and adolescent health services in Kenya, Uganda and Zambia**](#)

Shiphrah Kuria-Ndiritu, Sarah Karanja, Brenda Mubita, Tonny Kapsandui, John Kutna, Dona Anyona, Joyce Murerwa, Laura Ferguson

Research Article | published 25 Jan 2024 PLOS Global Public Health

<https://doi.org/10.1371/journal.pgph.0002740>

PLoS Medicine

<http://www.plosmedicine.org/>

(Accessed 27 Jan 2024)

[No new digest content identified]

PLoS Neglected Tropical Diseases

<http://www.plosntds.org/>

(Accessed 27 Jan 2024)

[**Vaccination coverage and adverse events following a reactive vaccination campaign against hepatitis E in Bentiu displaced persons camp, South Sudan**](#)

Robin C. Nesbitt, Vincent Kinya Asilaza, Etienne Gignoux, Aybüke Koyuncu, Priscillah Gitahi, Patrick Nkemenang, Jetske Duncker, Zelig Antier, Melat Haile, Primitive Gakima, Joseph F. Wamala, Fredrick Beden Loro, Duol Biem, Monica Rull, Andrew S. Azman, John Rumunu, Iza Ciglenecki

Research Article | published 22 Jan 2024 PLOS Neglected Tropical Diseases

<https://doi.org/10.1371/journal.pntd.0011661>

PLoS One

<http://www.plosone.org/>

[Accessed 27 Jan 2024]

[Interplay between vaccines and treatment for dengue control: An epidemic model](#)

Abdoulaye Sow, Cherif Diallo, Hocine Cherifi
Research Article | published 25 Jan 2024 PLOS ONE
<https://doi.org/10.1371/journal.pone.0295025>

[COVID-19 preventive measures in Rohingya refugee camps: An assessment of knowledge, attitude and practice](#)

Charls Erik Halder, Md Abeed Hasan, Yussuf Mohamed Mohamud, Marsela Nyawara, James Charles Okello, Md Nahid Mizan, Md Abu Sayum, Ahmed Hossain, Andrew Willam, Hamim Tassdik
Research Article | published 24 Jan 2024 PLOS ONE
<https://doi.org/10.1371/journal.pone.0282558>

PLoS Pathogens

<http://journals.plos.org/plospathogens/>
[Accessed 27 Jan 2024]
[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States

January 23, 2024 vol. 121 no. 4

<https://www.pnas.org/toc/pnas/121/4>
[New issue; No digest content identified]

PNAS Nexus

Volume 2, Issue 12, December 2023
<https://academic.oup.com/pnasnexus/issue/2/12>
[Reviewed earlier]

Prehospital & Disaster Medicine

Volume 38 - Issue 6 - December 2023
<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>
[Reviewed earlier]

Preventive Medicine

Volume 178 January 2024
<https://www.sciencedirect.com/journal/preventive-medicine/vol/178/suppl/C>
[Reviewed earlier]

Proceedings of the Royal Society B

10 January 2024 Volume 291 Issue 2014
<https://royalsocietypublishing.org/toc/rspb/current>
[Reviewed earlier]

Public Health

Volume 226 Pages e1-e6, 1-274 (January 2024)

<https://www.sciencedirect.com/journal/public-health/vol/226/suppl/C>

[Reviewed earlier]

Public Health Ethics

Volume 16, Issue 2, July 2023

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

Public Health Genomics

2023, Vol. 26, No. 1

<https://karger.com/phg/issue/26/1>

[Reviewed earlier]

Public Health Reports

Volume 139 Issue 1, January/February 2024

<https://journals.sagepub.com/toc/phrg/139/1>

[Reviewed earlier]

Qualitative Health Research

Volume 34 Issue 3, February 2024

<https://journals.sagepub.com/toc/QHR/current>

[Reviewed earlier]

Research Ethics

Volume 20 Issue 1, January 2024

<http://journals.sagepub.com/toc/reab/current>

[Reviewed earlier]

Reproductive Health

<http://www.reproductive-health-journal.com/content>

[Accessed 27 Jan 2024]

[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)

<https://www.paho.org/journal/en>

22 Jan 2024

[**Neonatal mortality in countries of the Americas, 2000–2020: trends, inequalities, and target-setting**](#)

Original research | English

Risk Analysis

Volume 44, Issue 1 Pages: 1-280 January 2024

<https://onlinelibrary.wiley.com/toc/15396924/current>

[Reviewed earlier]

Risk Management and Healthcare Policy

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 27 Jan 2024]

[Reviewed earlier]

Science

Volume 383| Issue 6681| 26 Jan 2024

<https://www.science.org/toc/science/current>

[New issue; No digest content identified]

Science and Engineering Ethics

Volume 29, Issue 6 December 2023

<https://link.springer.com/journal/11948/volumes-and-issues/29-6>

[Reviewed earlier]

Science Translational Medicine

Volume 16| Issue 731| 24 Jan 2024

<https://www.science.org/toc/stm/current>

[New issue; No digest content identified]

Scientific Reports

<https://www.nature.com/srep/articles?type=article>

[Accessed 27 Jan 2024]

[No new digest content identified]

Social Science & Medicine

Volume 340 January 2024

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/340/suppl/C>

[Reviewed earlier]

Systematic Reviews

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 27 Jan 2024]

[No new digest content identified]

Theoretical Medicine and Bioethics

Volume 44, Issue 6 December 2023

<https://link.springer.com/journal/11017/volumes-and-issues/44-6>

[Reviewed earlier]

Travel Medicine and Infectious Diseases

Volume 57 January–February 2024

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/57/suppl/C>

Research article Open access

[Predicting the next pandemic: VACCELERATE ranking of the World Health Organization's Blueprint for Action to Prevent Epidemics](#)

Jon Salmanton-García, Pauline Wipfler, Janina Leckler, Pontus Naucclér, ... Fabio Forghieri

Article 102676

Tropical Medicine & International Health

Volume 29, Issue 1 Pages: i-iv, 1-71 January 2024

<https://onlinelibrary.wiley.com/toc/13653156/current>

[Reviewed earlier]

Vaccine

Volume 42, Issue 2 Pages 65-402 (12 January 2024)

<https://www.sciencedirect.com/journal/vaccine/vol/42/issue/2>

[Reviewed earlier]

Vaccines

<https://www.mdpi.com/journal/vaccines>

[Accessed 27 Jan 2024]

Latest Articles [Selected]

Open Access Article

[Exploring Vaccination Challenges among Syrian Refugees in Jordan: Insights from Camps and Communities, and Perceived Parental Barriers to Childhood Vaccination Uptake](#)

by [Bayan Abdulhaq](#), et al.

Vaccines 2024, 12(2), 133; <https://doi.org/10.3390/vaccines12020133> (registering DOI) - 27 Jan 2024

Open Access Article

[Exploring Vaccination Challenges among Syrian Refugees in Jordan: Insights from Camps and Communities, and Perceived Parental Barriers to Childhood Vaccination Uptake](#)

by [Bayan Abdulhaq](#)

Vaccines 2024, 12(2), 133; <https://doi.org/10.3390/vaccines12020133> (registering DOI) - 27 Jan 2024

Value in Health

January 2024 Volume 27 Issue 1 p1-132

<https://www.valueinhealthjournal.com/current>

[Reviewed earlier]

World Development

Volume 175 March 2024

<https://www.sciencedirect.com/journal/world-development/vol/175/suppl/C>

[Reviewed earlier]

.....
.....

Contents [click to move among sections]

- :: [Milestones, Perspectives](#)*
- :: [WHO](#)*
- :: [Organization Announcements](#)*
- :: [Journal Watch](#)*
- :: [Pre-Print Servers](#)*

.....
.....

Pre-Print Servers

Gates Open Research

<https://gatesopenresearch.org/browse/articles>

[Accessed 27 Jan 2024]

Selected Research

[No new digest content identified]

medRxiv

<https://www.medrxiv.org/content/about-medrxiv>

[Accessed 27 Jan 2024]

[Filter: All articles]

[Dynamic Profiling and Prediction of Antibody Response to Booster Inactivated Vaccines by Microsample-driven Biosensor and Machine Learning](#)

Sumin Bian, Min Shang, Ying Tao, Pengbo Wang, Yankun Xu, Yao Wang, Zhida Shen, Mahamad Sawan

medRxiv 2024.01.25.24301760; doi: <https://doi.org/10.1101/2024.01.25.24301760>

[Evaluation of a new dengue 3 controlled human infection model for use in the evaluation of candidate dengue vaccines.](#)

Kristen K Pierce, Steve S Whitehead, Sean A. Diehl, Gill Naro, Marya P Carmolli, Helen He, Cecilia Tibery, Dorothy M Dickson, Beulah P Sabundayo, Beth D Kirkpatrick, Anna P Durbin

medRxiv 2023.06.07.23291100; doi: <https://doi.org/10.1101/2023.06.07.23291100> Revision

Abstract

All four serotypes of dengue virus (DENV) cause the full spectrum of disease. Therefore, vaccines must protect against all serotypes. To evaluate candidate vaccines, a human challenge model of dengue serotype 3 (rDEN30Δ30) was developed. All challenge virus recipients safely met the primary endpoint of viremia and secondary endpoints of rash and seroconversion to DENV-3.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

Clinicaltrials.gov [NCT02684383](https://clinicaltrials.gov/ct2/show/study/NCT02684383).

Funding Statement

This work was supported by the National Institute of Allergy and Infectious Disease Intramural Research Program, National Institutes of Health [contract no. HHSN272200900010C]

[Superspreading of SARS-CoV-2: a systematic review and meta-analysis of event attack rates and individual transmission patterns](#)

Clifton D McKee, Emma X Yu, Andrés Garcia, Jules Jackson, Aybüke Koyuncu, Sophie Rose, Andrew S Azman, Katie Lobner, Emma Sacks, Maria D Van Kerkhove, Emily S Gurley
medRxiv 2024.01.25.24301669; doi: <https://doi.org/10.1101/2024.01.25.24301669>

[Safety Monitoring of Bivalent COVID-19 mRNA Vaccines Among Recipients 6 months and Older in the United States](#)

Patricia C. Lloyd, Elizabeth R Smith, Joann F. Gruber, Michelle Ondari, Hui Lee Wong, Mao Hu, Tainya C. Clarke, Rowan McEvoy, Kandace L. Amend, Daniel C. Bleacher, Cheryl N. McMahill-Walraven, John D. Seeger, Alex Secora, Djeneba Audrey Djibo, Jennifer Song, Nandini Selvam, Jonathan P. DeShazo, Robin Clifford, Eugenio Abente, Yoganand Chillarige, Richard A. Forshee, Steven A. Anderson, Azadeh Shoabi
medRxiv 2024.01.24.24301676; doi: <https://doi.org/10.1101/2024.01.24.24301676>

[Immunogenicity and vaccine-serotype carriage prevalence after full or fractional doses of Pneumococcal Conjugate Vaccines in Kenyan infants: an individually randomised, controlled, non-inferiority trial](#)

Katherine E. Gallagher, Ruth Lucinde, Christian Bottomley, Mary Kaniu, Badaud Suaad, Mary Mutahi, Laura Mwalekwa, Sarah Ragab, Louise Twi-Yeboah, James A. Berkley, Mainga Hamaluba, Angela Karani, Jimmy Shangala, Mark Otiende, Elizabeth Gardiner, Daisy Mugo, Peter G. Smith, Collins Tabu, Fred Were, David Goldblatt, J. Anthony G. Scott FMedSci
medRxiv 2024.01.24.24301730; doi: <https://doi.org/10.1101/2024.01.24.24301730>

[Interrogating Changes in COVID-19 Vaccine Intent During the National Vaccine Rollout in the Philippines](#)

Alexandria Caple, Arnie Dimaano, Marc Martin Sagolili, April Anne Uy, Panjee Mariel Aguirre, Dean Alano, Kaila Andrine Baul, Giselle Sophia Camaya, Angelo Raine Carlos, Brent John Ciriaco, Princess Jerah Mae Clavo, Dominic Cuyugan, Cleinne Florence Geeseler Fermo, Paul Jeremy Lanete, Ardwayne Jurel La Torre, Thomas Loteyro, Raisa Mikaela Lua, Nicole Gayle Manansala, Raphael Mosquito, Alexa Marie Octaviano, Alexandra Erika Orfanel, Anne Elizabeth Papa, Gheyanna Merly Pascual, Mark Nhel Peralta, Aubrey Joy Sale, Sophia Lorraine Tendenilla, Maria Sofia Lauren Trinidad, Nicole Jan Trinidad, Daphne Louise Verano, Nicanor Austriaco
medRxiv 2024.01.20.24301539; doi: <https://doi.org/10.1101/2024.01.20.24301539>

[Strategic vaccine stockpiles for regional epidemics of emerging viruses: a geospatial modeling framework](#)

Colin J. Carlson, Romain Garnier, Andrew Tiu, Stephen Luby, Shweta Bansal
medRxiv 2024.01.19.24301505; doi: <https://doi.org/10.1101/2024.01.19.24301505>

Abstract

Multinational epidemics of emerging infectious diseases are increasingly common, due to anthropogenic pressure on ecosystems and the growing connectivity of human populations. Early and efficient vaccination can contain outbreaks and prevent mass mortality, but optimal vaccine stockpiling strategies are dependent on pathogen characteristics, reservoir ecology, and epidemic dynamics. Here, we model major regional outbreaks of Nipah virus and Middle East respiratory syndrome, and use these to develop a generalized framework for estimating vaccine stockpile needs based on spillover geography, spatially-heterogeneous healthcare capacity and spatially-distributed human mobility networks. Because outbreak sizes were highly skewed, we found that most outbreaks were readily contained (median stockpile estimate for MERS-CoV: 2,089 doses; Nipah: 1,882 doses), but the maximum estimated stockpile need in a highly unlikely large outbreak scenario was 2-3 orders of magnitude higher (MERS-CoV: ~87,000 doses; Nipah ~1.1 million doses). Sensitivity analysis revealed that stockpile needs were more dependent on basic epidemiological parameters (i.e., death and recovery rate) and healthcare availability than any uncertainty related to vaccine efficacy or deployment strategy. Our results highlight the value of

descriptive epidemiology for real-world modeling applications, and suggest that stockpile allocation should consider ecological, epidemiological, and social dimensions of risk.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This project was made possible with financial support provided by the Coalition for Epidemic Preparedness Innovations. CJC was additionally supported by NSF BII 2213854.

OSF Pre-prints

<https://osf.io/preprints/discover?provider=OSF&subject=bepress%7C%20Life%20Sciences>

[Provider Filter: OSF Pre-prints Subject filters: Arts & Humanities; Education, Life Sciences; Medicine and Health Sciences; Social and Behavioral Sciences]

We observe increasing levels of "posting pollution" by individuals, sometimes posting 10+ items of no value. We will resume selective monitoring beginning in September.

Wellcome Open Research

<https://wellcomeopenresearch.org/browse/articles>

[Accessed 27 Jan 2024]

Selected Research

Research Article Open Access

[REVISED-Conceptualizing expectations - Vietnam's responses during COVID-19 as an illustration](#) [version 2; peer review: 2 approved with reservations]

Hai Doan

* * * *

Think Tanks

Brookings [to 27 Jan 2024]

<http://www.brookings.edu/>

Research

No new digest content identified.

Center for Global Development [to 27 Jan 2024]

<https://www.cgdev.org/>

All Research [Selected]

No new digest content identified.

Chatham House [to 27 Jan 2024]

<https://www.chathamhouse.org/>

Selected Analysis, Comment, Events

No new digest content identified.

Council on Foreign Relations [to 27 Jan 2024]

<https://www.cfr.org/media/news-releases>

New Releases [Selected]

No new digest content identified.

CSIS [to 27 Jan 2024]

<https://www.csis.org/>

Reports [Selected]

No new digest content identified.

Kaiser Family Foundation [to 27 Jan 2024]

https://www.kff.org/search/?post_type=press-release

Newsroom

[What to Watch in 2024: The Latest Health Cost and Affordability Issues and Trends](#)

January 24, 2024 News Release

While issues of health care costs and affordability may not be at the forefront of this year's election issues, they remain a major concern among the public. About a quarter of Americans say they or a family member struggled to pay their medical bills just in the past year, and...

McKinsey Global Institute [to 27 Jan 2024]

<https://www.mckinsey.com/mgi/overview>

Latest Research

No new digest content identified.

ODI [Overseas Development Institute] [to 27 Jan 2024]

<https://odi.org/en/publications/>

Publications [Selected]

No new digest content identified.

Pew Research Center [to 27 Jan 2024]

<https://www.pewresearch.org/>

Latest Publications [Selected]

No new digest content identified.

Rand [to 27 Jan 2024]

<https://www.rand.org/pubs.html>

Published Research [Selected]

Report

[The Operational Risks of AI in Large-Scale Biological Attacks: Results of a Red-Team Study](#)

In this report, the authors share final results of a study of potential risks of artificial intelligence (AI) in the context of biological weapon attacks. The findings indicate that AI did not measurably change the operational risk of such an attack.

Jan 25, 2024

Christopher A. Mouton, Caleb Lucas, Ella Guest

Urban Institute [to 27 Jan 2024]

<https://www.urban.org/publications>

[New Research Publications - Selected](#)

Research Report

Supporting Community-Based Organizations in Advancing Vaccine Equity

January 26, 2024

Evaluation of Urban Institute's Technical Assistance and Grant Management Support in the First Year of the Partnering for Vaccine Equity Program

Annie Heinrichs, Ebonie Megibow, Amaya Taylor, Susanna Emmet, Arezo Azizi, Eva H. Allen

PDF: [https://www.urban.org/sites/default/files/2024-](https://www.urban.org/sites/default/files/2024-01/Supporting%20CBOs%20in%20Advancing%20Vaccine%20Equity.pdf)

[01/Supporting%20CBOs%20in%20Advancing%20Vaccine%20Equity.pdf](https://www.urban.org/sites/default/files/2024-01/Supporting%20CBOs%20in%20Advancing%20Vaccine%20Equity.pdf)

The Centers for Disease Control and Prevention (CDC) launched the Partnering for Vaccine Equity (P4VE) program in 2020 to address racial and ethnic disparities in adult immunization rates, particularly for COVID-19 and influenza. In 2021, P4VE directed \$156 million to over 500 national, state, and community-based organizations (CBOs) to improve equitable access to vaccination in communities by promoting vaccine confidence and addressing barriers to vaccination opportunities.

The Urban Institute (Urban) is one of several national intermediary entities responsible for recruiting, overseeing, and supporting CBOs participating in the P4VE program. In the first year of the P4VE initiative, the Urban Institute worked with 29 CBOs focused on addressing barriers to COVID-19 vaccines in racially and ethnically diverse and underresourced communities. This report describes and assesses Urban's technical assistance and grant management support delivered to CBO awardees to help them implement program activities, comply with federal grant requirements, and grow organizational capacity to promote vaccine equity...

World Economic Forum [to 27 Jan 2024]

<https://agenda.weforum.org/press/>

Media [Selected]

No new digest content identified.

.....
.....

Public Consultations/Call for Inputs/Call for Papers

Concept paper on the revision of the Non-clinical and Clinical Module of the influenza vaccines guideline (PDF/177.49 KB)

EMA

First published: 31/10/2023 **Consultation dates: 01/11/2023 to 30/01/2024**

Summary/Problem statement [Excerpt]

The proposed guideline will replace Guideline on influenza vaccines, non-clinical and clinical modules (EMA/CHMP/VWP/457259/2014).

...The current guideline text addresses collection of vaccine effectiveness data for approved vaccines by season. The collection of reliable data, especially brand-specific data, has proven difficult even within countries with high quality influenza disease surveillance. There is a need to rediscuss the feasibility of the current recommendations, while still acknowledging the utility of such data to detect unexpected effectiveness signals.

Overall, there is some degree of urgency to revise the guideline on non-clinical and clinical development of influenza vaccines. In particular, to add sections relevant to the development of mRNA-based influenza vaccines and to reflect on how lessons learned from the COVID-19 pandemic could be relevant to the development of influenza vaccines, including those intended only for pandemic usage.

Comments should be provided using this [EUSurvey form](#). For any technical issues, please contact the [EUSurvey Support](#)

Declaration of Helsinki – Phase I Public Comment Period

World Medical Association

In order to maximize input by all stakeholders and the public, we are providing two separate public comment periods. A phase 1 public comment period is being held now to address issues from the first few regional meetings, and a phase 2 comment period will follow in the spring when additional topics have been addressed.

Open Now: Phase 1 Public Comment Period **Due: 7 February 2024.**

The workgroup's proposed edits to date are now available for public comment. To submit your or your organization's feedback, download the [phase 1 public comment document](#)

Call for Papers: Establishing the impact of WHO's normative and standard-setting functions: a call for papers

WHO - Bull World Health Organ. 2023 Oct 1; 101(10): 618–618A. Published online 2023 Oct 1.

The deadline for submissions is 1 March 2024

Editorial

Lisa M Askie^a, Rebekah AL Thomas^a, Rok Ho Kim^a, Mubashar Sheikh^a, Jeremy Farrar^b

doi: 10.2471/BLT.23.290829 PMID: PMC10523809

Normative leadership is a core function of the World Health Organization's (WHO) mandate, as outlined in its founding principles.¹ This leadership role is realized by developing evidence-based and ethically sound guidelines as well as other normative products that guide Member States in their public health decisions and actions, and by ensuring their recommendations are implemented.² WHO exercises its capacity for normative leadership to influence the development of legal norms and health policy and practice within its Member States...

... In the past five years, WHO has initiated a major change process, driven by its current Thirteenth Global Programme of Work,⁶ the transformation agenda, and the need to respond to major global events including the coronavirus disease 2019 (COVID-19) pandemic and other crises. More recently, WHO has developed a comprehensive strategy to enhance its capacities and capabilities at country level, to ensure that its normative work drives measurable impact for all people more effectively.

Despite these initiatives, to date it is unclear whether these changes have improved WHO's credibility and impact as a normative organization. Questions remain as to how successful WHO's normative leadership role has been, how it can be further strengthened and how the impact of WHO's work in countries should be measured and rated in the future. The recent COVID-19 pandemic exposed both the strengths of and the challenges to WHO's normative leadership and global reach. While realizing the crucial role of WHO as a key directing and coordinating authority, the global health community has also witnessed the unprecedented rise of misinformation and mistrust in science.

Considering the spotlight on WHO's global normative leadership role during the pandemic,⁷ and looking to prepare for future threats such as the health effects of climate change and ongoing conflict situations, the Bulletin of the World Health Organization calls for papers to help shape and inform WHO's mandate going forward. Topics of interest include: where has WHO succeeded in its normative leadership role? In what specific areas has it successfully shaped global health, and why were these initiatives successful? Where has WHO normative guidance been less impactful? If so, why was this the case, and what lessons can be learnt to improve impact in the future? What does the future of WHO's normative function look like, particularly in the context of digital technology and artificial intelligence? What aspects of the Organization's mandate, structure, function and administration need to be further strengthened or changed?

The Bulletin welcomes contributions from all stakeholders including public health decision-makers, researchers, and civil society and community representatives. Articles that propose innovative but

feasible ways by which WHO can further strengthen its normative leadership and guidance role, are encouraged.

* * * *
* * * *

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (CVEP) / GE2P2 Global Foundation, which is solely responsible for its content.

.....

Copyright GE2P2 Global Foundation 2023. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

.....

CVEP is a program of the GE2P2 Global Foundation whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute, and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

* * * *
* * * *